On the evening of January 29, Allist (**688578SH) announced its 2023 annual results. According to the announcement, according to the preliminary calculation of the company's financial department, Allist is expected to achieve operating income of 20 in 20230.9 billion yuan, an increase of 12 over the same period of the previous year1.8 billion yuan, a year-on-year increase of 15398%；Net profit attributable to owners of the parent company is expected to be 6400 million yuan, a year-on-year increase of 39034%；The net profit attributable to owners of the parent company after deducting non-recurring gains and losses is expected to be 5900 million yuan, an increase of 643 over the same period last year31%。
Regarding the significant change in operating performance in 2023, the company said that this is due to the continuous increase in sales and a large increase in operating income after the first-line ** indication of the core product Vormetinib mesylate tablets was included in the national medical insurance catalog. At the same time, due to the continuous expansion of the company's sales scale, the associated scale effect has gradually reduced the cost and expense ratio, thereby promoting a substantial increase in net profit.
In this regard, some market analysts said that the 2023 annual performance forecast released by Allist sent a very positive signal to the outside world. The substantial increase in revenue and non-net profit attributable to the parent company shows that the company's innovative drugs in the field of oncology have been widely recognized by the market, especially the fist product Furmetinib mesylate tablets have been included in the medical insurance, which has a far-reaching impact on the company's subsequent development, in addition to expanding the market demand for the product, increasing sales volume and sales, it will also comprehensively enhance the core competitiveness of Allist, and have a significant boost to the company's future operating performance.
According to public information, Allist is an innovative drug company focusing on the field of oncology. Since its establishment, the company has adhered to independent innovation and established a complete new drug research and development system for scientifically validated targets, covering the discovery and optimization of lead drugs, the evaluation and establishment of drug candidates, drug preclinical and clinical research, drug registration and declaration, industrialization and commercialization. At present, the company is strategically focusing on the research and development of small molecule targeted innovative drugs for tumors, mainly building a R&D pipeline around common driver gene targets in non-small cell lung cancer, and is committed to becoming a leading innovative drug company in the field of small molecule targeted drugs for non-small cell lung cancer.
Disclaimer: This article is for informational purposes only and does not constitute investment advice.